Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Möhler

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics|June 10, 2008
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trialRalf-Dieter Hofheinz, Frederik Wenz, Nadine Lukan, et al.
Journal of Cancer Research and Clinical Oncology|August 7, 2013
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effectiveThomas C Wehler, Claudine Graf, Markus Möhler, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 29, 2020
Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?Liana M Bergholz, Peter Grimminger, Elsa Dikeoulia, et al.
Cancers|July 9, 2022
Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological ConsiderationsTiemo S Gerber, Lukas Müller, Fabian Bartsch, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 15, 2018
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trialMichael Nagel, Julia Schulz, Annett Maderer, et al.
Journal of Cancer Research and Clinical Oncology|March 13, 2017
HER2 testing in gastric cancer: results of a German expert meetingFlorian Lordick, Salah-Eddin Al-Batran, Manfred Dietel, et al.
Eclinicalmedicine|May 28, 2026
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 studyMiao-Zhen Qiu, Keun-Wook Lee, Markus Möhler, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 17, 2023
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancerFlorian Lordick, Salah-Eddin Al-Batran, Dirk Arnold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerDominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|June 10, 2008
Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trialRalf-Dieter Hofheinz, Frederik Wenz, Nadine Lukan, et al.
Journal of Cancer Research and Clinical Oncology|August 7, 2013
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effectiveThomas C Wehler, Claudine Graf, Markus Möhler, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|October 29, 2020
Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?Liana M Bergholz, Peter Grimminger, Elsa Dikeoulia, et al.
Cancers|July 9, 2022
Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological ConsiderationsTiemo S Gerber, Lukas Müller, Fabian Bartsch, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 15, 2018
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trialMichael Nagel, Julia Schulz, Annett Maderer, et al.
Journal of Cancer Research and Clinical Oncology|March 13, 2017
HER2 testing in gastric cancer: results of a German expert meetingFlorian Lordick, Salah-Eddin Al-Batran, Manfred Dietel, et al.
Eclinicalmedicine|May 28, 2026
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 studyMiao-Zhen Qiu, Keun-Wook Lee, Markus Möhler, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 17, 2023
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancerFlorian Lordick, Salah-Eddin Al-Batran, Dirk Arnold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal CancerDominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Pageof 3